SLC5A2 and cardiovascular disorder: Recent studies have shown promising results with the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in reducing the risk of cardiovascular disease and progression of DKD2,3.